Longboard Pharmaceuticals

Channeling innovation to change the course of neurological diseases

Welcome to Longboard Pharmaceuticals, a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases.

About

Longboard Pharmaceuticals, Inc. (Longboard) is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases.

Longboard was formed in January 2020 by Arena Pharmaceuticals, Inc. (Arena) to advance a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs). Longboard’s small molecule product candidates were discovered out of the same platform at Arena that represents a culmination of more than 20 years of GPCR research.

Longboard is evaluating LP352, an oral, centrally acting, 5-hydroxytryptamine 2c receptor subtype superagonist, in development for the potential treatment of developmental and epileptic encephalopathies. Longboard is also evaluating LP143, a centrally acting, fullcannabinoid type 2 receptor agonist, in development for the potential treatment of neurodegenerative diseases associated with neuroinflammation caused by microglial activation, and LP659, a centrally acting, sphingosine-1-phosphate receptor subtypes 1 and 5 modulator, in development for the potential treatment of central nervous system neuroinflammatory diseases. 

Management

Kevin Lind

President and CEO

Phil Perera, MD

Chief Medical Officer

Brandi L. Roberts

Chief Financial Officer

Chad Orevillo

Vice President and Head of Operations

Investors

Longboard’s investor syndicate includes Farallon Capital, Cormorant Asset Management, HBM Healthcare Investments, Highside Capital Management, and T. Rowe Price Associates, with participation from Arena Pharmaceuticals.

arena
farallon
cormorant
hbm
highside
troweprice

Pipeline

ProgramMechanism of ActionTherapeutic AreaDrug DiscoveryIND-EnablingEarly Clinical
LP352 Potentially most potent, selective 5-HT2C agonist Developmental and Epileptic Encephalopathies (DEEs) Refractory Focal Epilepsies

LP143 CB2 receptor agonist ALS, PD

LP659 S1P receptor modulator Multiple CNS neuroinflammatory disorders

Undisclosed - -

DrugMOAStage
LP352 Potentially most potent, selective 5-HT2C agonist Early Clinical
LP143 CB2 receptor agonist IND-Enabling
LP659 S1P receptor modulator IND-Enabling
Undisclosed -IND-Enabling

Careers

WE ARE COMMITTED TO IMPROVING LIVES.

WE STRIVE TO BE THE BEST POSSIBLE TEAMMATES AND COLLEAGUES.

WE ARE LOOKING FOR PEOPLE TO JOIN OUR TEAM WHO ARE JUST AS DYNAMIC, TALENTED, AND PASSIONATE AS WE ARE.

We are an equal-opportunity employer offering competitive benefits. Our open positions are listed below. To apply, please send your CV to [email protected] with the position you are applying for in the subject line.

If the position you are looking for is not listed, please check back frequently for new open positions, as our team is growing rapidly.

Contact

6154 Nancy Ridge Drive, San Diego, CA 92121
(619) 592-9775 | [email protected]